Rosa laevigata Michx. inhibits pulmonary arterial smooth muscle cell proliferation in hypertension by modulating the Src-AKT1 axis.
10.12122/j.issn.1673-4254.2025.09.09
- Author:
Ziwei YANG
1
;
Chang LÜ
2
;
Zhu DONG
1
;
Shulei JI
1
;
Shenghui BI
1
;
Xuehua ZHANG
1
;
Xiaowu WANG
1
Author Information
1. Department of Cardiovascular Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.
2. Department of Spinal Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China.
- Publication Type:Journal Article
- Keywords:
AKT1;
Src;
network pharmacology;
pulmonary hypertension;
smooth muscle cell proliferation
- MeSH:
Animals;
Cell Proliferation/drug effects*;
Proto-Oncogene Proteins c-akt/metabolism*;
Rats, Sprague-Dawley;
Pulmonary Artery/cytology*;
Male;
Rats;
Myocytes, Smooth Muscle/cytology*;
Hypertension, Pulmonary/pathology*;
Drugs, Chinese Herbal/pharmacology*;
Signal Transduction/drug effects*;
Muscle, Smooth, Vascular/cytology*;
src-Family Kinases/metabolism*;
Cells, Cultured
- From:
Journal of Southern Medical University
2025;45(9):1889-1902
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To investigate the synergistic mechanism of the traditional Chinese medicine Rosa laevigata Michx. (RLM) for treatment of pulmonary arterial hypertension (PAH).
METHODS:Network pharmacological analysis was carried out to screen the active ingredients of RLM and PAH disease targets and construct the "component-target-disease" interaction network, followed by gene enrichment analysis and molecular docking studies. In the cell experiments, primary cultures of rat pulmonary arterial smooth muscle cells were exposed to hypoxia for 24 h and treated with solvent or 100, 200 and 300 mg/mL RLM, and the changes in cell proliferation were detected using Western blotting for PCNA and immunofluorescence staining. In the animal experiment, male SD rats were randomized into 5 control group, monocrotaline (MCT) solvent group, and MCT with RLM (100, 200 and 300 mg/mL) treatment groups. HE staining and immunofluorescence staining were used to observe histopathological changes in the pulmonary blood vessels of the rats.
RESULTS:Seven core active ingredients (including β-sitosterol and kaempferol) in RLM and 39 key disease targets were identified, and molecular docking showed that SRC was a high-affinity target. KEGG enrichment analysis showed that the differential genes were significantly enriched in calcium signaling and PI3K-AKT pathways. In rat pulmonary arterial smooth muscle cells, hypoxic exposure significantly up-regulated cellular expression of PCNA and phosphorylation levels of Src and AKT1, which were obviously lowered by RLM treatment. In RLM-treated rat models, the mean pulmonary artery pressure and right ventricular hypertrophy index (Fulton index) were significantly reduced, the tricuspid annular plane systolic excursion (TAPSE) was improved, and pulmonary vascular wall thickening and fibrosis were obviously ameliorated.
CONCLUSIONS:RLM inhibits pulmonary arterial smooth muscle cell proliferation in rat models of hypertension possibly by regulating the Src-AKT1 axis, suggesting the potential of RLM as a new natural drug for treatment of pulmonary hypertension.
